186 related articles for article (PubMed ID: 29399393)
1. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.
Morisada M; Clavijo PE; Moore E; Sun L; Chamberlin M; Van Waes C; Hodge JW; Mitchell JB; Friedman J; Allen CT
Oncoimmunology; 2018; 7(3):e1395996. PubMed ID: 29399393
[TBL] [Abstract][Full Text] [Related]
2. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.
Patel P; Sun L; Robbins Y; Clavijo PE; Friedman J; Silvin C; Van Waes C; Cook J; Mitchell J; Allen C
Oncoimmunology; 2019; 8(11):e1638207. PubMed ID: 31646086
[TBL] [Abstract][Full Text] [Related]
3. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8
Wang H; Lin X; Luo Y; Sun S; Tian X; Sun Y; Zhang S; Chen J; Zhang J; Liu X; Liu H; Gong Y; Xie C
Immunotherapy; 2019 Feb; 11(2):101-118. PubMed ID: 30511887
[TBL] [Abstract][Full Text] [Related]
4. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade.
Zhao X; Shao C
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32992835
[TBL] [Abstract][Full Text] [Related]
6. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
7. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Oweida A; Lennon S; Calame D; Korpela S; Bhatia S; Sharma J; Graham C; Binder D; Serkova N; Raben D; Heasley L; Clambey E; Nemenoff R; Karam SD
Oncoimmunology; 2017; 6(10):e1356153. PubMed ID: 29123967
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
[TBL] [Abstract][Full Text] [Related]
9. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment.
Luo R; Firat E; Gaedicke S; Guffart E; Watanabe T; Niedermann G
Clin Cancer Res; 2019 Dec; 25(23):7243-7255. PubMed ID: 31506388
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.
Dosset M; Vargas TR; Lagrange A; Boidot R; Végran F; Roussey A; Chalmin F; Dondaine L; Paul C; Lauret Marie-Joseph E; Martin F; Ryffel B; Borg C; Adotévi O; Ghiringhelli F; Apetoh L
Oncoimmunology; 2018; 7(6):e1433981. PubMed ID: 29872568
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Kang SH; Keam B; Ahn YO; Park HR; Kim M; Kim TM; Kim DW; Heo DS
Oncoimmunology; 2019; 8(1):e1515057. PubMed ID: 30546955
[TBL] [Abstract][Full Text] [Related]
14. Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.
Morisada M; Chamberlin M; Allen C
Head Neck; 2018 Jun; 40(6):1321-1334. PubMed ID: 29461655
[TBL] [Abstract][Full Text] [Related]
15. The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade.
Dovedi SJ; Illidge TM
Oncoimmunology; 2015 Jul; 4(7):e1016709. PubMed ID: 26140246
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
17. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
Tachinami H; Nishii N; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Tomihara K; Noguchi M; Azuma M
Oral Oncol; 2019 Apr; 91():21-28. PubMed ID: 30926058
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
